Chicago, Illinois-based Mondelez International, Inc. (MDLZ) is a global snack food and beverage company. Valued at a market cap of $89.1 billion, the company manufactures, markets, and sells a wide range of products across several categories, including chocolates, biscuits, gum, candy, beverages, and cheese & grocery items. Its portfolio features many iconic brands such as Oreo, Cadbury Dairy Milk, Ritz, LU, and CLIF Bar, among others. It is scheduled to announce its fiscal Q2 earnings for 2025 on Tuesday, Jul. 29.

Prior to this event, analysts project this snack food and beverage company to report a profit of $0.67 per share, down 22.1% from $0.86 per share in the year-ago quarter. The company has exceeded Wall Street’s bottom-line estimates in three of the last four quarters, while missing on another occasion. Its earnings of $0.74 per share in the previous quarter outpaced the consensus estimates by 13.9%. 

For the full year, analysts expect Mondelez to report EPS of $3.02, down 10.1% from $3.36 in fiscal 2024. Nonetheless, its EPS is expected to rebound in fiscal 2026 and grow by 10.3% year-over-year to $3.33. 

Shares of MDLZ have gained 2.8% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 11.9% return and the Consumer Staples Select Sector SPDR Fund’s (XLP) 6.1% uptick over the same time frame.

Mondelez delivered mixed Q1 earnings results on Apr. 29, and its shares rose 3.8% in the following trading session. The company’s revenue improved marginally year-over-year to $9.3 billion but fell short of the analyst estimates by a slight margin due to unfavourable currency-related items and the end of a temporary distributor deal tied to its divested gum business. However, on the brighter side, its organic revenue grew 3.1% from the same period last year. Additionally, while its adjusted EPS of $0.74 declined 20.4% from the year-ago quarter, it still surpassed the forecasted figure by a notable margin of 13.9%. Fewer outstanding shares, lower taxes, and contributions from an acquisition, partially offset operating declines and higher interest and other expenses and led to its bottom-line beat. 

Wall Street analysts are moderately optimistic about MDLZ’s stock, with a "Moderate Buy" rating overall. Among 25 analysts covering the stock, 15 recommend "Strong Buy," two indicate "Moderate Buy," seven suggest "Hold,” and one advises a "Strong Sell” rating. The mean price target for MDLZ is $72.12, which indicates a 4.8% potential upside from the current levels.